Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
CARsgen makes history as China approves world's first CAR-T therapy for solid tumors
The world’s first CAR-T therapy for solid tumors has passed muster in China, with the country's National Medical Products Administration (NMPA) giving the green light to CARsgen Therapeutics’ satri | The Claudin18.2-targeted therapy is the first CAR-T to win global approval in a solid tumor.
TL;DRAI
CARsgen gets first CAR-T approval for solid tumors from China's NMPA, median PFS 3.25 vs 1.77 months (gastric cancer). Validates cell therapy for solid tumors and signals Chinese biotech maturity; reshapes global licensing partnerships and biotech investment strategy.
1,102 words~5 min read
